                         SEQUENCE LISTING

<110>  Silverback Therapeutics, Inc.
       Smith, Sean Wesley
       Coburn, Craig Alan
       Baum, Peter Robert
       Dubose, Robert Finley
 
<120>  ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF

<130>  860234.405WO

<140>  PCT
<141>  2020-07-16

<150>  62/874,886
<151>  2019-07-16

<160>  398   

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab HCDR1

<400>  1

Gly Phe Thr Phe Ser Ser Tyr Thr 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab HCDR2

<400>  2

Ile Ser Tyr Asp Gly Asn Asn Lys 
1               5               


<210>  3
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab HCDR3

<400>  3

Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr 
1               5                   10      


<210>  4
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab LCDR1

<400>  4

Gln Ser Val Gly Ser Ser Tyr 
1               5           


<210>  5
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab LCDR2

<400>  5

Ser Ser Tyr 
1           


<210>  6
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab LCDR3

<400>  6

Gln Gln Tyr Gly Ser Ser Pro Trp Thr 
1               5                   


<210>  7
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab HCDR1

<400>  7

Gly Ile Thr Phe Ser Asn Ser Gly 
1               5               


<210>  8
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab HCDR2

<400>  8

Ile Trp Tyr Asp Gly Ser Lys Arg 
1               5               


<210>  9
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab HCDR3

<400>  9

Ala Thr Asn Asp Asp Tyr 
1               5       


<210>  10
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab LCDR1

<400>  10

Gln Ser Val Ser Ser Tyr Leu 
1               5           


<210>  11
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab LCDR2

<400>  11

Asp Ala Ser 
1           


<210>  12
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab LCDR3

<400>  12

Gln Gln Ser Ser Asn Trp Pro Arg Thr 
1               5                   


<210>  13
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab HCDR1

<400>  13

Gly Tyr Thr Phe Thr Asn Tyr Tyr 
1               5               


<210>  14
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab HCDR2

<400>  14

Ile Asn Pro Ser Asn Gly Gly Thr 
1               5               


<210>  15
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab HCDR3

<400>  15

Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr 
1               5                   10              


<210>  16
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab LCDR1

<400>  16

Lys Gly Val Ser Thr Ser Gly Tyr Ser Tyr 
1               5                   10  


<210>  17
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab LCDR2

<400>  17

Leu Ala Ser 
1           


<210>  18
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab LCDR3

<400>  18

Gln His Ser Arg Asp Leu Pro Leu Thr 
1               5                   


<210>  19
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab HCDR1

<400>  19

Gly Tyr Thr Phe Thr Asp Ser Tyr 
1               5               


<210>  20
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab HCDR2

<400>  20

Met Tyr Pro Asp Asn Gly Asp Ser 
1               5               


<210>  21
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab HCDR3

<400>  21

Val Leu Ala Pro Arg Trp Tyr Phe Ser Val 
1               5                   10  


<210>  22
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab LCDR1

<400>  22

Gln Asp Ile Ser Asn Tyr 
1               5       


<210>  23
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab LCDR2

<400>  23

Tyr Thr Ser 
1           


<210>  24
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab LCDR3

<400>  24

Gln Gln Gly His Thr Leu Pro Pro Thr 
1               5                   


<210>  25
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab HCDR1

<400>  25

Gly Phe Thr Phe Ser Ser Tyr Asp 
1               5               


<210>  26
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab HCDR2

<400>  26

Ile Trp Tyr Asp Gly Ser Asn Lys 
1               5               


<210>  27
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab HCDR3

<400>  27

Ala Arg Gly Ser Gly Asn Trp Gly Phe Phe Asp Tyr 
1               5                   10          


<210>  28
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab LCDR1

<400>  28

Gln Gly Ile Ser Arg Trp 
1               5       


<210>  29
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab LCDR2

<400>  29

Ala Ala Ser 
1           


<210>  30
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab LCDR3

<400>  30

Gln Gln Tyr Asn Thr Tyr Pro Arg Thr 
1               5                   


<210>  31
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab HCDR1

<400>  31

Gly Tyr Thr Phe Thr Ser Tyr Arg 
1               5               


<210>  32
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab HCDR2

<400>  32

Ile Asn Pro Ser Thr Gly Tyr Thr 
1               5               


<210>  33
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab HCDR3

<400>  33

Ala Arg Gly Gly Gly Val Phe Asp Tyr 
1               5                   


<210>  34
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab LCDR1

<400>  34

Ser Ser Ser Ile Ser Tyr 
1               5       


<210>  35
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab LCDR2

<400>  35

Thr Thr Ser 
1           


<210>  36
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab LCDR3

<400>  36

His Gln Arg Ser Thr Tyr Pro Leu Thr 
1               5                   


<210>  37
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR HCDR1

<400>  37

Ser Tyr Gly Met His 
1               5   


<210>  38
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR HCDR2

<400>  38

Val Ile Trp Tyr Glu Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  39
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR HCDR3

<400>  39

Gly Gly Ser Met Val Arg Gly Asp Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10                  15  


<210>  40
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR LCDR1

<400>  40

Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala 
1               5                   10      


<210>  41
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR LCDR2

<400>  41

Asp Ala Ser Ser Leu Glu Ser 
1               5           


<210>  42
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR LCDR3

<400>  42

Gln Gln Phe Asn Ser Tyr Pro Tyr Thr 
1               5                   


<210>  43
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-3 HCDR1

<400>  43

Asp Tyr Tyr Trp Asn 
1               5   


<210>  44
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-4 HCDR2

<400>  44

Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  45
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-5 HCDR3

<400>  45

Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro 
1               5                   10          


<210>  46
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-6 LCDR1

<400>  46

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  47
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-7 LCDR2

<400>  47

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  48
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-8 LCDR3

<400>  48

Gln Gln Arg Ser Asn Trp Pro Leu Thr 
1               5                   


<210>  49
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LPXTG recognition motif


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Xaa can be any naturally occurring amino acid

<400>  49

Leu Pro Xaa Thr Gly 
1               5   


<210>  50
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab HCDR1

<400>  50

Gly Tyr Ser Phe Ser Thr Tyr Trp 
1               5               


<210>  51
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab HCDR2

<400>  51

Ile Tyr Pro Gly Asp Ser Tyr Thr 
1               5               


<210>  52
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab HCDR3

<400>  52

Ala Arg Gly Tyr Gly Ile Phe Asp Tyr 
1               5                   


<210>  53
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab LCDR1

<400>  53

Asn Ile Gly Asp Gln Tyr 
1               5       


<210>  54
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab LCDR2

<400>  54

Gln Asp Lys 
1           


<210>  55
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab LCDR3

<400>  55

Ala Thr Tyr Thr Gly Phe Gly Ser Leu Ala Val 
1               5                   10      


<210>  56
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 HCDR1

<400>  56

Gly Tyr Thr Phe Thr Asp Tyr Asn 
1               5               


<210>  57
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 HCDR2

<400>  57

Ile Asn Pro Asn Tyr Glu Ser Thr 
1               5               


<210>  58
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 HCDR3

<400>  58

Arg Asp Lys Gly Trp Tyr Phe Asp Val 
1               5                   


<210>  59
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 LCDR1

<400>  59

Ser Ser Val Lys Asn 
1               5   


<210>  60
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 LCDR2

<400>  60

Tyr Thr Ser 
1           


<210>  61
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 LCDR3

<400>  61

Gln Gln Phe Thr Ser Ser Pro Tyr Thr 
1               5                   


<210>  62
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 HCDR1

<400>  62

Gly Phe Ser Leu Ser Thr Ser Gly Met Gly 
1               5                   10  


<210>  63
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 HCDR2

<400>  63

Ile Trp Trp Asp Asp Asp Lys 
1               5           


<210>  64
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 HCDR3

<400>  64

Ala Arg Leu Thr Gly Thr Arg Tyr Phe Asp Tyr 
1               5                   10      


<210>  65
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 LCDR1

<400>  65

Gln Asp Ile Asn Lys Phe 
1               5       


<210>  66
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 LCDR2

<400>  66

Tyr Thr Ser 
1           


<210>  67
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 LCDR3

<400>  67

Leu Gln Tyr Gly Asn Leu Trp Thr 
1               5               


<210>  68
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 HCDR1

<400>  68

Gly Tyr Thr Phe Thr Asp Tyr Ser 
1               5               


<210>  69
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 HCDR2

<400>  69

Ile Asn Thr Glu Thr Gly Glu Pro 
1               5               


<210>  70
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 HCDR3

<400>  70

Ala Thr Tyr Tyr Gly Ser Ser Tyr Val Pro Asp Tyr 
1               5                   10          


<210>  71
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 LCDR1

<400>  71

Gln Asn Val Gly Thr Ala 
1               5       


<210>  72
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 LCDR2

<400>  72

Trp Thr Ser 
1           


<210>  73
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antibody to TNFR2 variant 3 LCDR3

<400>  73

Gln Tyr Ser Asp Tyr Pro Tyr Thr 
1               5               


<210>  74
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 HCDR1

<400>  74

Gly Tyr Thr Phe Thr Asp Tyr 
1               5           


<210>  75
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 HCDR2

<400>  75

Trp Val Asp Pro Glu Tyr Gly Ser 
1               5               


<210>  76
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 HCDR3

<400>  76

Ala Arg Asp Asp Gly Ser Tyr Ser Pro Phe Asp Tyr 
1               5                   10          


<210>  77
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 LCDR1 (major)

<400>  77

Gln Asn Ile Asn Lys Tyr 
1               5       


<210>  78
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 LCDR2 (major)

<400>  78

Tyr Thr Ser 
1           


<210>  79
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 LCDR3 (major)

<400>  79

Leu Gln Tyr Val Asn Leu Leu Thr 
1               5               


<210>  80
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 LCDR1 (minor)

<400>  80

Glu Asn Val Val Thr Tyr 
1               5       


<210>  81
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 LCDR2 (minor)

<400>  81

Gly Ala Ser 
1           


<210>  82
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 LCDR3 (minor)

<400>  82

Gln Gly Tyr Ser Tyr Pro Tyr Thr 
1               5               


<210>  83
<211>  118
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab VH

<400>  83

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Thr Phe Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Gly Trp Leu Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  84
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ipilumumab VL

<400>  84

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Phe Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  85
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab VH

<400>  85

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Asp Cys Lys Ala Ser Gly Ile Thr Phe Ser Asn Ser 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Lys Arg Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Asn Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  86
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  nivolumab VL

<400>  86

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Ser Asn Trp Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  87
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab VH

<400>  87

Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  88
<211>  111
<212>  PRT
<213>  Artificial sequence

<220>
<223>  pembrolizumab VL

<400>  88

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
        35                  40                  45              


Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  89
<211>  118
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Atezolizumab VH

<400>  89

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 
            20                  25                  30          


Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  90
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Atezolizumab VL

<400>  90

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  91
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Durvalumab VH

<400>  91

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  92
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Durvalumab VL

<400>  92

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro 
                85                  90                  95      


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  93
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  MDX-1106 VH

<400>  93

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr 
            20                  25                  30          


Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  94
<211>  106
<212>  PRT
<213>  Artificial sequence

<220>
<223>  MDX-1106 VL

<400>  94

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105     


<210>  95
<211>  117
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 VH

<400>  95

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Ile Asn Pro Asn Tyr Glu Ser Thr Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Val Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Phe Tyr Cys 
                85                  90                  95      


Ala Arg Asp Lys Gly Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  96
<211>  106
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 1 VL

<400>  96

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly 
1               5                   10                  15      


Glu Lys Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Lys Asn Met 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Ser Asp Ala Ser Pro Lys Leu Trp Ile Tyr 
        35                  40                  45              


Tyr Thr Ser Asn Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Gly Glu 
65                  70                  75                  80  


Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Phe Thr Ser Ser Pro Tyr Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys 
            100                 105     


<210>  97
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 VH

<400>  97

Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Phe Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Gln Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val 
65                  70                  75                  80  


Phe Leu Lys Leu Thr Ser Val Val Thr Ala Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Leu Thr Gly Thr Arg Tyr Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Leu Thr Val Ser Ser 
        115                 


<210>  98
<211>  106
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 2 VL

<400>  98

Asp Val Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Lys Phe 
            20                  25                  30          


Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile 
        35                  40                  45              


His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Lys Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Gly Asn Leu Trp Thr 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr 
            100                 105     


<210>  99
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 VH

<400>  99

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 
1               5                   10                  15      


Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 
    50                  55                  60                  


Lys Gly Arg Phe Ala Phe Ser Ser Glu Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Ile Asn Asn Leu Lys Asn Asp Asp Thr Thr Thr Tyr Phe Cys 
                85                  90                  95      


Ala Thr Tyr Tyr Gly Ser Ser Tyr Val Pro Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Ser Leu Thr Val Ser Ser 
        115                 


<210>  100
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 3 VL

<400>  100

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln His Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Trp Thr Ser Ser Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr Phe Cys His Gln Tyr Ser Asp Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  101
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 VH

<400>  101

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Gly Arg Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Ile Met His Trp Val Lys Gln Ser Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Trp Val Asp Pro Glu Tyr Gly Ser Thr Asp Tyr Ala Glu Lys Phe 
    50                  55                  60                  


Lys Lys Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Asp Asp Gly Ser Tyr Ser Pro Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Val Met Val Thr Val Ser Ser 
        115                 


<210>  102
<211>  106
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 VL (major)

<400>  102

Asp Ile Gln Met Thr Gln Ser Pro Pro Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Lys Val Thr Ile Thr Cys Gln Ala Ser Gln Asn Ile Asn Lys Tyr 
            20                  25                  30          


Ile Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Arg Tyr Thr Ser Thr Leu Glu Ser Gly Thr Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Val Glu Ser 
65                  70                  75                  80  


Glu Asp Ile Ala Ser Tyr Tyr Cys Leu Gln Tyr Val Asn Leu Leu Thr 
                85                  90                  95      


Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys 
            100                 105     


<210>  103
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 4 VL (minor)

<400>  103

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 
1               5                   10                  15      


Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr 
            20                  25                  30          


Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  104
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 5 VH

<400>  104

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Glu Asn Gly Ser Asp Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Gly Ala Val Ser Tyr Phe Asp Val Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  105
<211>  109
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to TNFR2 variant 5 VL

<400>  105

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Leu Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 
            100                 105                 


<210>  106
<211>  117
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab VH

<400>  106

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser 
            20                  25                  30          


Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Asp Met Tyr Pro Asp Asn Gly Asp Ser Ser Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Arg Glu Arg Val Thr Ile Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Val Leu Ala Pro Arg Trp Tyr Phe Ser Val Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  107
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vonlerolizumab VL

<400>  107

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Arg Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Thr Leu Pro Pro 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  108
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  TRX518 VL

<400>  108

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Thr Asp Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  109
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  TRX518 VH

<400>  109

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
        35                  40                  45              


Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 
65                  70                  75                  80  


Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Thr Arg Arg Tyr Phe Pro Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  110
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  TRX518 VH

<400>  110

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 
1               5                   10                  15      


Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
            20                  25                  30          


Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
        35                  40                  45              


Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Gln Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 
65                  70                  75                  80  


Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Thr Arg Arg Tyr Phe Pro Phe Ala Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  111
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-3 VH

<400>  111

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  112
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to LAG-3 VL

<400>  112

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys 
            100                 105         


<210>  113
<211>  140
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 1 VH

<400>  113

Met Ala Val Leu Ala Leu Leu Phe Cys Leu Val Thr Phe Pro Ser Cys 
1               5                   10                  15      


Ile Leu Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala 
            20                  25                  30          


Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu 
        35                  40                  45              


Thr Gly Tyr Gly Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu 
    50                  55                  60                  


Glu Trp Leu Gly Met Ile Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ser 
65                  70                  75                  80  


Val Leu Thr Ser Arg Leu Arg Ile Ser Lys Asp Asn Ser Asn Ser Gln 
                85                  90                  95      


Val Phe Leu Lys Met Asn Ser Leu Gln Val Asp Asp Thr Ala Arg Tyr 
            100                 105                 110         


Tyr Cys Ala Arg Asp Arg Asn Tyr Tyr Asp Tyr Asp Gly Ala Met Asp 
        115                 120                 125             


Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 
    130                 135                 140 


<210>  114
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 1 VL

<400>  114

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Ile Asn Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Met Ile Trp Ser Asp Gly Ser Thr Asp Tyr Asn Ser Val Leu Thr 
    50                  55                  60                  


Ser Arg Leu Arg Ile Ser Lys Asp Asn Ser Asn Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Val Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Arg Asn Tyr Tyr Asp Tyr Asp Gly Ala Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  115
<211>  127
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 2 VH

<400>  115

Met Lys Phe Pro Ser Gln Leu Leu Leu Phe Leu Leu Phe Arg Ile Thr 
1               5                   10                  15      


Gly Ile Ile Cys Asp Ile Gln Val Thr Gln Ser Ser Ser Tyr Leu Ser 
            20                  25                  30          


Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His 
        35                  40                  45              


Ile Lys Asn Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro 
    50                  55                  60                  


Arg Leu Leu Val Ser Gly Ala Thr Ser Leu Glu Ala Gly Val Pro Ser 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Lys Asn Phe Thr Leu Ser Ile Thr 
                85                  90                  95      


Ser Leu Gln Thr Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp 
            100                 105                 110         


Ser Thr Pro Trp Thr Phe Gly Gly Gly Thr Thr Leu Glu Ile Arg 
        115                 120                 125         


<210>  116
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 2 VL

<400>  116

Asp Ile Gln Val Thr Gln Ser Ser Ser Tyr Leu Ser Val Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Asp His Ile Lys Asn Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Arg Leu Leu Val 
        35                  40                  45              


Ser Gly Ala Thr Ser Leu Glu Ala Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Lys Asn Phe Thr Leu Ser Ile Thr Ser Leu Gln Thr 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Trp Ser Thr Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Thr Leu Glu Ile Arg 
            100                 105         


<210>  117
<211>  126
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 3 VH

<400>  117

Glu Val Gln Leu Val Gln Pro Gly Ala Glu Leu Arg Asn Ser Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Arg Phe Thr Ser Tyr 
            20                  25                  30          


Tyr Ile Asp Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asp Pro Glu Asp Gly Gly Thr Lys Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Val Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asn Glu Trp Glu Thr Val Val Val Gly Asp Leu Met Tyr Glu 
            100                 105                 110         


Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 
        115                 120                 125     


<210>  118
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 3 VL

<400>  118

Asp Ile Gln Met Thr Gln Ser Pro Thr Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Asp Ser Leu Pro Val 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys 
            100                 105         


<210>  119
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 3 VL

<400>  119

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Val Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Arg Leu Gln Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Ala Ser Ala Pro Val 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Gly Val Glu Leu Lys 
            100                 105         


<210>  120
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 3 VL

<400>  120

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Gly Thr Ser Arg Leu Lys Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Ala Pro Val 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys 
            100                 105         


<210>  121
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 3 VL

<400>  121

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Pro Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Thr Ile Ser Ser Phe 
            20                  25                  30          


Leu Ala Trp Tyr His Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Arg Ala Ser Ile Pro Gln Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Gly Gly Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Val Ser Ala Pro Pro 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys 
            100                 105         


<210>  122
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GARP variant 3 VL

<400>  122

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Asn Ile Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Arg Leu Lys Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Gly Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Gly Thr Tyr Tyr Cys Gln Gln Tyr Ala Ser Val Pro Val 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Leu Lys 
            100                 105         


<210>  123
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to 4-1BB variant 1 VH

<400>  123

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Gly Gly Tyr Val Thr Tyr Asn Pro Ser Leu Glu 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Tyr Gly Pro Gly Asn Tyr Asp Trp Tyr Phe Asp Leu Trp Gly 
            100                 105                 110         


Arg Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  124
<211>  109
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to 4-1BB variant 1 VL

<400>  124

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 


<210>  125
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to 4-1BB variant 2 VH

<400>  125

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Asp Ile Lys Asn Asp Gly Ser Tyr Thr Asn Tyr Ala Pro Ser Leu 
    50                  55                  60                  


Thr Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Leu Thr Gly Thr Trp Gly Gln Gly Thr Met Val Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  126
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to 4-1BB variant 2 VL

<400>  126

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Ser Ser 
            20                  25                  30          


Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Pro Pro Lys Leu Leu Ile Tyr Tyr Ala Ser Thr Arg Gln Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Leu Gln 
                85                  90                  95      


Tyr Asp Arg Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
            100                 105                 110         


Lys 
    


<210>  127
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab VH

<400>  127

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Thr Tyr 
            20                  25                  30          


Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe 
    50                  55                  60                  


Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Tyr Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  128
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Utomilumab VL

<400>  128

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Lys Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Thr Gly Phe Gly Ser Leu 
                85                  90                  95      


Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  129
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ICOS variant 1 VL

<400>  129

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Arg Leu 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Val Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Trp 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  130
<211>  125
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ICOS variant 1 VH

<400>  130

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro His Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Thr Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr His Asp Ala Phe 
            100                 105                 110         


Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 
        115                 120                 125 


<210>  131
<211>  117
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ICOS variant 2 VH

<400>  131

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Trp Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Val Trp Val 
        35                  40                  45              


Ser Asn Ile Asp Glu Asp Gly Ser Ile Thr Glu Tyr Ser Pro Phe Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Arg Trp Gly Arg Phe Gly Phe Asp Ser Trp Gly Gln Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  132
<211>  111
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ICOS variant 2 VL

<400>  132

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Ser Gly 
            20                  25                  30          


Ser Phe Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Phe Tyr Ala Ser Thr Arg His Thr Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His His His Tyr 
                85                  90                  95      


Asn Ala Pro Pro Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105                 110     


<210>  133
<211>  118
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vorsetuzumab VH

<400>  133

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Lys Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Ala Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Tyr Gly Asp Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  134
<211>  111
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Vorsetuzumab VL

<400>  134

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 
            20                  25                  30          


Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg 
                85                  90                  95      


Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110     


<210>  135
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Rinucumab VH

<400>  135

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Ser 
            20                  25                  30          


Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Ser Ile Tyr Tyr Arg Gly Ser Thr Asn Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Ser Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Tyr Leu Lys Val Ser Ser Val Thr Ala Val Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Gln Asn Gly Ala Ala Arg Pro Ser Trp Phe Asp Pro Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  136
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Rinucumab VL

<400>  136

Glu Ile Val Leu Thr Gln Ser Pro Asp Thr Ile Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Ile 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Ile Tyr Gly Ala Ser Ser Arg Val Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Val Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Gly Ile Ser Pro 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Arg 
            100                 105             


<210>  137
<211>  117
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Oleclumab VH

<400>  137

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Tyr Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Leu Gly Tyr Gly Arg Val Asp Glu Trp Gly Arg Gly Thr Leu 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  138
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Oleclumab VL

<400>  138

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 
1               5                   10                  15      


Arg Val Thr Ile Ser Cys Ser Gly Ser Leu Ser Asn Ile Gly Arg Asn 
            20                  25                  30          


Pro Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 
        35                  40                  45              


Ile Tyr Leu Asp Asn Leu Arg Leu Ser Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 
65                  70                  75                  80  


Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser His 
                85                  90                  95      


Pro Gly Trp Thr Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 110 


<210>  139
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to CD73 VL

<400>  139

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  140
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to CD73 VH

<400>  140

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Leu Tyr Asp Gly Ser Asn Lys Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Ser Ser Trp Tyr Pro Asp Ser Phe Asp Ile Trp Gly 
            100                 105                 110         


Gln Gly Thr Met Val Thr Val Ser Ser 
        115                 120     


<210>  141
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daratumumab VH

<400>  141

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Asn Ser Phe 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Lys Asp Lys Ile Leu Trp Phe Gly Glu Pro Val Phe Asp Tyr Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  142
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daratumumab VL

<400>  142

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  143
<211>  117
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Etaracizumab VH

<400>  143

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Lys Val Ser Ser Gly Gly Gly Ser Thr Tyr Tyr Leu Asp Thr Val 
    50                  55                  60                  


Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg His Leu His Gly Ser Phe Ala Ser Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  144
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Etaracizumab VL

<400>  144

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn Phe 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Arg Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Gly Ser Trp Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  145
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Intetumumab VH

<400>  145

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Arg Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Val Asn Ile Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Ala Arg Gly Ser Tyr Ala Phe Asp Ile Trp Gly Gln Gly 
            100                 105                 110         


Thr Met Val Thr Val Ser Ser 
        115                 


<210>  146
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Intetumumab VL

<400>  146

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105             


<210>  147
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB8 VH

<400>  147

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Val Phe Ser Arg Tyr 
            20                  25                  30          


Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Ser Ser Leu 
    50                  55                  60                  


Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Leu Ile Thr Thr Glu Asp Tyr Trp Gly Gln Gly Thr Thr Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  148
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB8 VL

<400>  148

Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Ala Asn Arg Leu Val Asp Gly Val Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  149
<211>  124
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ontuxizumab VH

<400>  149

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Val Ile His Trp Val Lys Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Asp Asp Asp Thr Thr Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Arg Val Thr Met Leu Val Asp Thr Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Arg Leu Ser Ser Val Thr Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Asn Ser Tyr Asp Gly Tyr Phe Asp Tyr Ser Met Asp 
            100                 105                 110         


Tyr Trp Gly Ser Gly Thr Pro Val Thr Val Ser Ser 
        115                 120                 


<210>  150
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Ontuxizumab VL

<400>  150

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Val Gly Thr Ala 
            20                  25                  30          


Val Ala Trp Leu Gln Gln Thr Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Thr Asn Tyr Pro Met 
                85                  90                  95      


Tyr Thr Phe Gly Gln Gly Thr Lys Val Gln Ile Lys 
            100                 105             


<210>  151
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 1 VH

<400>  151

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 
            20                  25                  30          


Ser Val Thr Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 
        35                  40                  45              


Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 
    50                  55                  60                  


Val Ser Val Lys Gly Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 
65                  70                  75                  80  


Gln Phe Tyr Leu Gln Leu Lys Ser Val Thr Pro Glu Asp Ala Ala Val 
                85                  90                  95      


Tyr Tyr Cys Ala Arg Asp Ser Ser Ile Leu Tyr Gly Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  152
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 1 VH

<400>  152

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 
            20                  25                  30          


Ser Val Thr Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 
        35                  40                  45              


Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala 
    50                  55                  60                  


Val Ser Val Lys Gly Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 
65                  70                  75                  80  


Gln Phe Tyr Leu Gln Leu Lys Ser Val Thr Pro Glu Asp Ala Ala Val 
                85                  90                  95      


Tyr Tyr Cys Ala Arg Asp Ser Ser Ile Leu Tyr Gly Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser 
        115                 120 


<210>  153
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 1 VL

<400>  153

Gln Ala Val Leu Thr Gln Pro Ser Ser Leu Ser Ala Ser Pro Gly Ala 
1               5                   10                  15      


Ser Ala Ser Leu Thr Cys Thr Leu Pro Ser Gly Ile Asn Val Gly Thr 
            20                  25                  30          


Tyr Arg Ile Phe Trp Phe Gln Gln Lys Pro Gly Ser Pro Pro Gln Tyr 
        35                  40                  45              


Leu Leu Ser Tyr Lys Ser Asp Ser Asp Asn His Gln Gly Ser Gly Val 
    50                  55                  60                  


Pro Ser Arg Phe Ser Gly Ser Lys Asp Ala Ser Ala Asn Ala Gly Ile 
65                  70                  75                  80  


Leu Leu Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys 
                85                  90                  95      


Met Ile Trp His Ser Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu 
            100                 105                 110         


Thr Val Leu 
        115 


<210>  154
<211>  122
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 2 VH

<400>  154

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Asn Pro Asn Arg Gly Gly Thr Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ala Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Thr Ala Ser Leu Lys Ile Ala Ala Val Gly Thr Phe Asp Cys Trp 
            100                 105                 110         


Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120         


<210>  155
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 2 VL

<400>  155

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Ser Lys Gln Tyr Ala 
            20                  25                  30          


Phe Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Thr Lys Arg Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Ala Asp 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Ser Gly Thr Tyr 
                85                  90                  95      


Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 
            100                 105         


<210>  156
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 3 VH

<400>  156

Glu Val Gln Leu Val Glu Thr Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Thr His 
            20                  25                  30          


Gly Met Tyr Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Tyr Asp Gly Ser Asp Lys Lys Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr 
65                  70                  75                  80  


Leu Glu Met Ser Ser Val Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
                85                  90                  95      


Phe Cys Arg Arg Asp Ala Phe Asp Leu Trp Gly Gln Gly Thr Met Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  157
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 3 VL

<400>  157

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Lys Tyr Ala 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Glu Asp Thr Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Thr Met Ala Thr Leu Thr Ile Ser Gly Ala Gln Val Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Thr Asp Ser Ser Gly Asn Tyr 
                85                  90                  95      


Trp Val Phe Gly Gly Gly Thr Glu Val Thr Val Leu 
            100                 105             


<210>  158
<211>  124
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 4 VH

<400>  158

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Glu Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 
            20                  25                  30          


Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Gly Arg Ile Lys Thr Lys Ser Asp Gly Gly Thr Thr Asp Tyr Ala Ala 
    50                  55                  60                  


Pro Val Arg Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Thr 
65                  70                  75                  80  


Leu Phe Leu Glu Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Ile Tyr 
                85                  90                  95      


Tyr Cys Phe Ile Thr Val Ile Val Val Ser Ser Glu Ser Pro Leu Asp 
            100                 105                 110         


His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 


<210>  159
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 4 VL

<400>  159

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Ser Gly Asp Glu Leu Pro Lys Gln Tyr Ala 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Lys Asp Arg Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Tyr Ser Ile Asn Thr Tyr 
                85                  90                  95      


Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  160
<211>  125
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 5 VH

<400>  160

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 
            20                  25                  30          


Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Ser Tyr Ile Ser Ser Gly Ser Ser Tyr Thr Asn Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Ser Val Tyr 
65                  70                  75                  80  


Leu Glu Val Asn Gly Leu Thr Val Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Arg Tyr Gly Asp Arg Glu Met Ala Thr Ile Gly Gly Phe 
            100                 105                 110         


Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125 


<210>  161
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 5 VL

<400>  161

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Ser Gly Asp Ala Leu Pro Lys Gln Tyr Ala 
            20                  25                  30          


Tyr Trp Tyr Gln Gln Ser Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Ser Gly Gly Thr Ser 
                85                  90                  95      


Arg Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             


<210>  162
<211>  124
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 6 VH

<400>  162

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Ser Thr Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Leu Val Ser Gly Asp Ser Ile Asn Ser His 
            20                  25                  30          


Tyr Trp Ser Trp Leu Arg Gln Ser Pro Gly Arg Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Tyr Tyr Thr Gly Pro Thr Asn Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Ser Ile Ser Leu Gly Thr Ser Lys Asp Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Arg Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asn Lys Val Phe Trp Arg Gly Ser Asp Phe Tyr Tyr Tyr Met Asp 
            100                 105                 110         


Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  163
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 6 VL

<400>  163

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Ala Asn Asn 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Met Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Val Thr Ser His 
                85                  90                  95      


His Met Tyr Ile Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110 


<210>  164
<211>  129
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 7 VH

<400>  164

His Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asn 
            20                  25                  30          


Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Gly Ala Arg Trp Gln Ala Arg Pro Ala Thr Arg Ile Asp 
            100                 105                 110         


Gly Val Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser 
        115                 120                 125             


Ser 
    


<210>  165
<211>  129
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 7 VH

<400>  165

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asn 
            20                  25                  30          


Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Gly Ala Arg Trp Gln Ala Arg Pro Ala Thr Arg Ile Asp 
            100                 105                 110         


Gly Val Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser 
        115                 120                 125             


Ser 
    


<210>  166
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 7 VH

<400>  166

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Trp Ser Arg Ser Gly Tyr Tyr Leu Pro Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  167
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 7 VL

<400>  167

Glu Thr Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Thr Arg Asn 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
        35                  40                  45              


Met Tyr Gly Ala Ser Asn Arg Ala Ala Gly Val Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Ser Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  168
<211>  112
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to FAP variant 7 VL

<400>  168

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
            20                  25                  30          


Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro His Leu Leu Ile Phe Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 
                85                  90                  95      


Leu Gln Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  169
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.11F V78A VH

<400>  169

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  170
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.12F V78A, M80I, E81Q VH

<400>  170

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  171
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin av variant 1 VH

<400>  171

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Arg Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Val Asn Ile Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Ala Arg Gly Ser Tyr Ala Phe Asp Ile Trp Gly Gln Gly 
            100                 105                 110         


Thr Met Val Thr Val Ser Ser 
        115                 


<210>  172
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin av variant 1 VL

<400>  172

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105             


<210>  173
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin av variant 2 VL

<400>  173

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Lys Ile His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  174
<211>  118
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin av variant 2 VH

<400>  174

Gln Val Gln Leu Gln Gln Ser Gly Gly Glu Leu Ala Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Phe 
            20                  25                  30          


Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Arg Ser Gly Tyr Thr Glu Tyr Asn Glu Ile Phe 
    50                  55                  60                  


Arg Asp Lys Ala Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ser Phe Leu Gly Arg Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Thr Val Thr Val Ser Ser 
        115             


<210>  175
<211>  124
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 1 VH

<400>  175

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 
            20                  25                  30          


Val Tyr Tyr Trp Thr Trp Ile Arg Gln His Pro Gly Asn Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Lys Gln Phe 
65                  70                  75                  80  


Ser Leu Asn Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Glu Gly Pro Leu Arg Gly Asp Tyr Tyr Tyr Gly Leu Asp 
            100                 105                 110         


Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  176
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 1 VL

<400>  176

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Gly Gln Thr Ile Ser Ser Arg 
            20                  25                  30          


Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu 
        35                  40                  45              


Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
    50                  55                  60                  


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65                  70                  75                  80  


Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
                85                  90                  95      


Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  177
<211>  128
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 2 VH

<400>  177

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 
            20                  25                  30          


Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Tyr Arg Gly Pro Ala Ala Gly Arg Gly Asp Phe Tyr Tyr 
            100                 105                 110         


Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 125             


<210>  178
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 2 VL

<400>  178

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Phe Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Asp Gly Lys Thr Tyr Leu Cys Trp Tyr Leu Gln Lys Pro Gly Gln Pro 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
                85                  90                  95      


Ile Gln Leu Pro Trp Ala Phe Phe Gly Gln Gly Thr Lys Val Glu Ile 
            100                 105                 110         


Lys 
    


<210>  179
<211>  125
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 3 VH

<400>  179

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Gly Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Leu Ala Ala Arg Arg Gly Asp Tyr Tyr Tyr Tyr Gly Met 
            100                 105                 110         


Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 125 


<210>  180
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 3 VL

<400>  180

Ser Ser Glu Leu Thr Gln Asp Pro Val Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Leu 
            20                  25                  30          


Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 
                85                  90                  95      


Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105         


<210>  181
<211>  125
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 4 VH

<400>  181

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 
            20                  25                  30          


Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu 
        35                  40                  45              


Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Tyr Asn Asn Pro Ser 
    50                  55                  60                  


Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  


Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      


Cys Ala Arg Val Ala Thr Gly Arg Ala Asp Tyr His Phe Tyr Ala Met 
            100                 105                 110         


Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 125 


<210>  182
<211>  106
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to Integrin avB6 variant 4 VL

<400>  182

Ser Tyr Glu Leu Thr Gln Pro Ser Ser Val Ser Val Ser Pro Gly Gln 
1               5                   10                  15      


Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Ser Ala 
            20                  25                  30          


Arg Trp Phe His Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu 
65                  70                  75                  80  


Asp Glu Ala Ala Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Leu Val 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105     


<210>  183
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab VH

<400>  183

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ser Gly Asn Trp Gly Phe Phe Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Leu Val Thr Val Ser Ser 
        115                 


<210>  184
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Varlilumab VL

<400>  184

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Arg Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Thr Tyr Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  185
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab VH

<400>  185

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Arg Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Gly Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  186
<211>  106
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Daclizumab VL

<400>  186

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Tyr Met 
            20                  25                  30          


His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr 
        35                  40                  45              


Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp 
65                  70                  75                  80  


Asp Phe Ala Thr Tyr Tyr Cys His Gln Arg Ser Thr Tyr Pro Leu Thr 
                85                  90                  95      


Phe Gly Gln Gly Thr Lys Val Glu Val Lys 
            100                 105     


<210>  187
<211>  124
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR VH

<400>  187

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Glu Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Ser Met Val Arg Gly Asp Tyr Tyr Tyr Gly Met Asp 
            100                 105                 110         


Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120                 


<210>  188
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to GITR VL

<400>  188

Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Ser Tyr Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  189
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huM25 to LRRC15 VH

<400>  189

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Lys Phe Ser Ser Tyr 
            20                  25                  30          


Trp Ile Glu Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Leu Pro Gly Ser Asp Thr Thr Asn Tyr Asn Glu Lys Phe 
    50                  55                  60                  


Lys Asp Arg Ala Thr Phe Thr Ser Asp Thr Ser Ile Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Arg Gly Asn Tyr Arg Ala Trp Phe Gly Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  190
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huM25 to LRRC15 VL

<400>  190

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gly Ala Val Lys Phe Leu Ile 
        35                  40                  45              


Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Ala Leu Pro Trp 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  191
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 VH

<400>  191

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Leu Val Tyr Pro Tyr Ile Gly Gly Thr Asn Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Asp Asn Lys Tyr Asp Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  192
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 VL

<400>  192

Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 
            20                  25                  30          


Ser Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Ile Lys Tyr Ala Ser Ser Leu Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Glu Gln Ser Trp 
                85                  90                  95      


Glu Ile Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110 


<210>  193
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 VH

<400>  193

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
            20                  25                  30          


Trp Met His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Met Ile His Pro Asn Ser Gly Ser Thr Lys His Asn Glu Lys Phe 
    50                  55                  60                  


Arg Gly Lys Ala Thr Leu Thr Val Asp Glu Ser Thr Thr Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Ser Asp Phe Gly Asn Tyr Arg Trp Tyr Phe Asp Val Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  194
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 VL

<400>  194

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ser Ser Asn Asn 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Val Leu Ile 
        35                  40                  45              


Lys Tyr Val Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  195
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 VH

<400>  195

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr 
            20                  25                  30          


Tyr Ile His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Leu Val Tyr Pro Tyr Ile Gly Gly Ser Ser Tyr Asn Gln Gln Phe 
    50                  55                  60                  


Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Asp Asn Asn Tyr Asp Ala Met Asp Tyr Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  196
<211>  110
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 VL

<400>  196

Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 
            20                  25                  30          


Thr Tyr Asn Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 
        35                  40                  45              


Lys Leu Leu Val Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Asp 
    50                  55                  60                  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
65                  70                  75                  80  


Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His His Thr Trp 
                85                  90                  95      


Glu Ile Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110 


<210>  197
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 VH

<400>  197

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Ser Leu Thr Ser Tyr 
            20                  25                  30          


Gly Val His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met 
    50                  55                  60                  


Ser Arg Leu Thr Ile Ser Lys Glu Asn Ala Lys Ser Ser Val Tyr Leu 
65                  70                  75                  80  


Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Met Tyr Tyr Cys Ala 
                85                  90                  95      


Thr His Met Ile Thr Glu Asp Tyr Tyr Gly Met Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Val Thr Val Ser Ser 
        115                 120 


<210>  198
<211>  112
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 VL

<400>  198

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1               5                   10                  15      


Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 
            20                  25                  30          


Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
        35                  40                  45              


Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
    50                  55                  60                  


Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65                  70                  75                  80  


Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln 
                85                  90                  95      


Ser Tyr Asn Leu Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210>  199
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 HCDR1

<400>  199

Asp Tyr Tyr Ile His 
1               5   


<210>  200
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 HCDR2

<400>  200

Leu Val Tyr Pro Tyr Ile Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  201
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 HCDR3

<400>  201

Gly Asp Asn Lys Tyr Asp Ala Met Asp Tyr 
1               5                   10  


<210>  202
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 LCDR1

<400>  202

Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His 
1               5                   10                  15  


<210>  203
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 LCDR2

<400>  203

Tyr Ala Ser Ser Leu Glu Ser 
1               5           


<210>  204
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.4.1 to LRRC15 LCDR3

<400>  204

Glu Gln Ser Trp Glu Ile Arg Thr 
1               5               


<210>  205
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 HCDR1

<400>  205

Asn Tyr Trp Met His 
1               5   


<210>  206
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 HCDR2

<400>  206

Met Ile His Pro Asn Ser Gly Ser Thr Lys His Asn Glu Lys Phe Arg 
1               5                   10                  15      


Gly 
    


<210>  207
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 HCDR3

<400>  207

Ser Asp Phe Gly Asn Tyr Arg Trp Tyr Phe Asp Val 
1               5                   10          


<210>  208
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 LCDR1

<400>  208

Arg Ala Ser Gln Ser Ser Ser Asn Asn Leu His 
1               5                   10      


<210>  209
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 LCDR2

<400>  209

Tyr Val Ser Gln Ser Ile Ser 
1               5           


<210>  210
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.12.1 to LRRC15 LCDR3

<400>  210

Gln Gln Ser Asn Ser Trp Pro Phe Thr 
1               5                   


<210>  211
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 HCDR1

<400>  211

Asp Tyr Tyr Ile His 
1               5   


<210>  212
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 HCDR2

<400>  212

Leu Val Tyr Pro Tyr Ile Gly Gly Ser Ser Tyr Asn Gln Gln Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  213
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 HCDR3

<400>  213

Gly Asp Asn Asn Tyr Asp Ala Met Asp Tyr 
1               5                   10  


<210>  214
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 LCDR1

<400>  214

Arg Ala Ser Gln Ser Val Ser Thr Ser Thr Tyr Asn Tyr Met His 
1               5                   10                  15  


<210>  215
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 LCDR2

<400>  215

Tyr Ala Ser Asn Leu Glu Ser 
1               5           


<210>  216
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody huAD208.14.1 to LRRC15 LCDR3

<400>  216

His His Thr Trp Glu Ile Arg Thr 
1               5               


<210>  217
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 HCDR1

<400>  217

Ser Tyr Gly Val His 
1               5   


<210>  218
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 HCDR2

<400>  218

Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met Ser 
1               5                   10                  15      


<210>  219
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 HCDR3

<400>  219

His Met Ile Thr Glu Asp Tyr Tyr Gly Met Asp Tyr 
1               5                   10          


<210>  220
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 LCDR1

<400>  220

Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr Leu 
1               5                   10                  15      


Ala 
    


<210>  221
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 LCDR2

<400>  221

Trp Ala Ser Thr Arg Glu Ser 
1               5           


<210>  222
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody hu139.10 to LRRC15 LCDR3

<400>  222

Lys Gln Ser Tyr Asn Leu Pro Thr 
1               5               


<210>  223
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD210.40.9 to LRRC15 HCDR1

<400>  223

Asn Tyr Trp Leu Gly 
1               5   


<210>  224
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD210.40.9 to LRRC15 HCDR2

<400>  224

Asp Ile Tyr Pro Gly Gly Gly Asn Thr Tyr Tyr Asn Glu Lys Leu Lys 
1               5                   10                  15      


Gly 
    


<210>  225
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD210.40.9 to LRRC15 HCDR3

<400>  225

Trp Gly Asp Lys Lys Gly Asn Tyr Phe Ala Tyr 
1               5                   10      


<210>  226
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD210.40.9 to LRRC15 LCDR1

<400>  226

Thr Ala Ser Ser Ser Val Tyr Ser Ser Tyr Leu His 
1               5                   10          


<210>  227
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD210.40.9 to LRRC15 LCDR2

<400>  227

Ser Thr Ser Asn Leu Ala Ser 
1               5           


<210>  228
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD210.40.9 to LRRC15 LCDR3

<400>  228

His Gln Tyr His Arg Ser Pro Thr 
1               5               


<210>  229
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD209.9.1 to LRRC15 HCDR1

<400>  229

Asn Phe Gly Met Asn 
1               5   


<210>  230
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD209.9.1 to LRRC15 HCDR2

<400>  230

Trp Ile Asn Leu Tyr Thr Gly Glu Pro Thr Phe Ala Asp Asp Phe Lys 
1               5                   10                  15      


Gly 
    


<210>  231
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD209.9.1 to LRRC15 HCDR3

<400>  231

Lys Gly Glu Thr Tyr Tyr Arg Tyr Asp Gly Phe Ala Tyr 
1               5                   10              


<210>  232
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD209.9.1 to LRRC15 LCDR1

<400>  232

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr His Leu Tyr 
1               5                   10                  15      


<210>  233
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD209.9.1 to LRRC15 LCDR2

<400>  233

Arg Met Ser Asn Leu Ala Ser 
1               5           


<210>  234
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody muAD209.9.1 to LRRC15 LCDR3

<400>  234

Met Gln Leu Leu Glu Tyr Pro Tyr Thr 
1               5                   


<210>  235
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody mAb-C to ASGR1 HCDR1

<400>  235

Ser Tyr Ala Met Ser 
1               5   


<210>  236
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody mAb-C to ASGR1 HCDR2

<400>  236

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  237
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody mAb-C to ASGR1 HCDR3

<400>  237

Asp Phe Ser Ser Arg Arg Trp Tyr Leu Glu Tyr 
1               5                   10      


<210>  238
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody mAb-C to ASGR1 LCDR1

<400>  238

Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala Ser 
1               5                   10      


<210>  239
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody mAb-C to ASGR1 LCDR2

<400>  239

Gly Lys Asn Asn Arg Pro Ser 
1               5           


<210>  240
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody mAb-C to ASGR1 LCDR3

<400>  240

Asn Ser Leu Glu Arg Ile Gly Tyr Leu Ser Tyr Val 
1               5                   10          


<210>  241
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 HCDR1

<400>  241

Gly Tyr Tyr Met His 
1               5   


<210>  242
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 HCDR2

<400>  242

Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  243
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 HCDR2

<400>  243

Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  244
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 HCDR2

<400>  244

Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  245
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 HCDR3

<400>  245

Val Asn Phe Tyr Tyr 
1               5   


<210>  246
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 LCDR1

<400>  246

Lys Ala Ser Gln Val Ile Asn Ser Tyr Leu Ser 
1               5                   10      


<210>  247
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 LCDR2

<400>  247

Arg Ala Asn Thr Leu Val Asp 
1               5           


<210>  248
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 LCDR2

<400>  248

Arg Ala Asn Thr Leu Val Ser 
1               5           


<210>  249
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 LCDR2

<400>  249

Arg Ala Asn Thr Leu Val Glu 
1               5           


<210>  250
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody G2D to ASGR1 LCDR3

<400>  250

Leu Gln Tyr Ala Glu Phe Pro Tyr Thr 
1               5                   


<210>  251
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 HCDR1

<400>  251

Ser Tyr Thr Met His 
1               5   


<210>  252
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 HCDR2

<400>  252

Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  253
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 HCDR3

<400>  253

Lys Phe Asp Tyr 
1               


<210>  254
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 LCDR1

<400>  254

Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser 
1               5                   10      


<210>  255
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 LCDR2

<400>  255

Arg Ala Asn Arg Leu Val Asp 
1               5           


<210>  256
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 LCDR2

<400>  256

Arg Ala Asn Arg Leu Val Glu 
1               5           


<210>  257
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody K2E to ASGR1 LCDR3

<400>  257

Leu Gln Tyr Asp Glu Phe Pro Phe Thr 
1               5                   


<210>  258
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody J4F to ASGR1 HCDR1

<400>  258

Ser Tyr Trp Ile Asn 
1               5   


<210>  259
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody J4F to ASGR1 HCDR2

<400>  259

Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe Lys 
1               5                   10                  15      


Asp 
    


<210>  260
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody J4F to ASGR1 HCDR3

<400>  260

Lys Pro Asn Phe Asp Val 
1               5       


<210>  261
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody J4F to ASGR1 LCDR1

<400>  261

Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala 
1               5                   10      


<210>  262
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody J4F to ASGR1 LCDR2

<400>  262

Ser Ala Ser Tyr Arg Phe Ser 
1               5           


<210>  263
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody J4F to ASGR1 LCDR3

<400>  263

Gln Gln Tyr Asn Ser Tyr Pro Leu Thr 
1               5                   


<210>  264
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 HCDR1

<400>  264

Ser Asp Tyr Ala Trp Asn 
1               5       


<210>  265
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 HCDR2

<400>  265

Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  266
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 HCDR3

<400>  266

Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr 
1               5                   10          


<210>  267
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 LCDR1

<400>  267

Arg Ala Ser Glu Asn Ile Tyr Ser Asn Leu Ala 
1               5                   10      


<210>  268
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 LCDR2

<400>  268

Ala Ala Thr Asn Leu Ala Asp 
1               5           


<210>  269
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 LCDR2

<400>  269

Ala Ala Thr Asn Leu Ala Ser 
1               5           


<210>  270
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 LCDR2

<400>  270

Ala Ala Thr Asn Leu Ala Glu 
1               5           


<210>  271
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody L4L to ASGR1 LCDR3

<400>  271

Gln His Phe Trp Gly Thr Pro Pro Trp Thr 
1               5                   10  


<210>  272
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody H8K to ASGR1 HCDR1

<400>  272

Ser Asp Tyr Ala Trp Asn 
1               5       


<210>  273
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody H8K to ASGR1 HCDR2

<400>  273

Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  274
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody H8K to ASGR1 HCDR3

<400>  274

Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
1               5                   10                  


<210>  275
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody H8K to ASGR1 LCDR1

<400>  275

Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala 
1               5                   10      


<210>  276
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody H8K to ASGR1 LCDR2

<400>  276

Asn Ala Lys Thr Leu Ala Glu 
1               5           


<210>  277
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody H8K to ASGR1 LCDR3

<400>  277

Gln His His Tyr Gly Thr Pro Leu Thr 
1               5                   


<210>  278
<211>  330
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Human IgG1 Heavy Chain Constant Region

<400>  278

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  279
<211>  330
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Human IgG1null Heavy Chain Constant Region L117A L118A G120A 
       K205A

<400>  279

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1               5                   10                  15      


Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
    50                  55                  60                  


Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65                  70                  75                  80  


Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
                85                  90                  95      


Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
            100                 105                 110         


Pro Ala Pro Glu Ala Ala Gly Ala Pro Ser Val Phe Leu Phe Pro Pro 
        115                 120                 125             


Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145                 150                 155                 160 


Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
                165                 170                 175     


Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
            180                 185                 190         


His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn 
        195                 200                 205             


Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
    210                 215                 220                 


Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 
225                 230                 235                 240 


Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
                245                 250                 255     


Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
            260                 265                 270         


Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
        275                 280                 285             


Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
    290                 295                 300                 


Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305                 310                 315                 320 


Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
                325                 330 


<210>  280
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Human Kappa Light Chain Constant Domain

<400>  280

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
1               5                   10                  15      


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
        35                  40                  45              


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
                85                  90                  95      


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
            100                 105         


<210>  281
<211>  330
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Mouse IgG2a Heavy Chain Constant Region

<400>  281

Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly 
1               5                   10                  15      


Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser 
        35                  40                  45              


Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu 
    50                  55                  60                  


Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile 
65                  70                  75                  80  


Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys 
                85                  90                  95      


Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys 
            100                 105                 110         


Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro 
        115                 120                 125             


Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys 
    130                 135                 140                 


Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp 
145                 150                 155                 160 


Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg 
                165                 170                 175     


Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln 
            180                 185                 190         


His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn 
        195                 200                 205             


Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly 
    210                 215                 220                 


Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu 
225                 230                 235                 240 


Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met 
                245                 250                 255     


Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu 
            260                 265                 270         


Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe 
        275                 280                 285             


Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn 
    290                 295                 300                 


Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr 
305                 310                 315                 320 


Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys 
                325                 330 


<210>  282
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Mouse Kappa Light Chain Constant Domain

<400>  282

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu 
1               5                   10                  15      


Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe 
            20                  25                  30          


Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg 
        35                  40                  45              


Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 
65                  70                  75                  80  


Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 
                85                  90                  95      


Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 
            100                 105         


<210>  283
<211>  331
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Rat IgG2b Heavy Chain Constant Region

<400>  283

Ala Gln Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly 
1               5                   10                  15      


Asp Thr Thr Ser Ser Thr Val Thr Leu Gly Cys Leu Val Lys Gly Tyr 
            20                  25                  30          


Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ala Leu Ser Ser 
        35                  40                  45              


Asp Val His Thr Phe Pro Ala Val Leu Gln Ser Gly Leu Tyr Thr Leu 
    50                  55                  60                  


Thr Ser Ser Val Thr Ser Ser Thr Trp Pro Ser Gln Thr Val Thr Cys 
65                  70                  75                  80  


Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Val Glu 
                85                  90                  95      


Arg Arg Asn Gly Gly Ile Gly His Lys Cys Pro Thr Cys Pro Thr Cys 
            100                 105                 110         


His Lys Cys Pro Val Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Ile 
        115                 120                 125             


Phe Pro Pro Lys Pro Lys Asp Ile Leu Leu Ile Ser Gln Asn Ala Lys 
    130                 135                 140                 


Val Thr Cys Val Val Val Asp Val Ser Glu Glu Glu Pro Asp Val Gln 
145                 150                 155                 160 


Phe Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln 
                165                 170                 175     


Pro Arg Glu Glu Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Ala Leu 
            180                 185                 190         


Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys 
        195                 200                 205             


Val Asn Asn Lys Ala Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys 
    210                 215                 220                 


Pro Lys Gly Leu Val Arg Lys Pro Gln Val Tyr Val Met Gly Pro Pro 
225                 230                 235                 240 


Thr Glu Gln Leu Thr Glu Gln Thr Val Ser Leu Thr Cys Leu Thr Ser 
                245                 250                 255     


Gly Phe Leu Pro Asn Asp Ile Gly Val Glu Trp Thr Ser Asn Gly His 
            260                 265                 270         


Ile Glu Lys Asn Tyr Lys Asn Thr Glu Pro Val Met Asp Ser Asp Gly 
        275                 280                 285             


Ser Phe Phe Met Tyr Ser Lys Leu Asn Val Glu Arg Ser Arg Trp Asp 
    290                 295                 300                 


Ser Arg Ala Pro Phe Val Cys Ser Val Val His Glu Gly Leu His Asn 
305                 310                 315                 320 


His His Val Glu Lys Ser Ile Ser Arg Pro Pro 
                325                 330     


<210>  284
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Rat kappa Light Chain Constant Domain

<400>  284

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Thr Glu 
1               5                   10                  15      


Gln Leu Ala Thr Gly Gly Ala Ser Val Val Cys Leu Met Asn Asn Phe 
            20                  25                  30          


Tyr Pro Arg Asp Ile Ser Val Lys Trp Lys Ile Asp Gly Thr Glu Arg 
        35                  40                  45              


Arg Asp Gly Val Leu Asp Ser Val Thr Asp Gln Asp Ser Lys Asp Ser 
    50                  55                  60                  


Thr Tyr Ser Met Ser Ser Thr Leu Ser Leu Thr Lys Ala Asp Tyr Glu 
65                  70                  75                  80  


Ser His Asn Leu Tyr Thr Cys Glu Val Val His Lys Thr Ser Ser Ser 
                85                  90                  95      


Pro Val Val Lys Ser Phe Asn Arg Asn Glu Cys 
            100                 105         


<210>  285
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 VH

<400>  285

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Phe Ser Ser Arg Arg Trp Tyr Leu Glu Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  286
<211>  109
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 VL

<400>  286

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 
1               5                   10                  15      


Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 
            20                  25                  30          


Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 
    50                  55                  60                  


Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Glu Arg Ile Gly Tyr Leu 
                85                  90                  95      


Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105                 


<210>  287
<211>  120
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to mzASGR1 VH

<400>  287

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1               5                   10                  15      


Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asp Phe Ser Ser Arg Arg Trp Tyr Leu Glu Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Thr Leu Thr Val Ser Ser 
        115                 120 


<210>  288
<211>  109
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to mzASGR1 VL

<400>  288

Gln Ala Val Leu Thr Gln Glu Pro Ala Leu Ser Val Ser Leu Gly Gln 
1               5                   10                  15      


Thr Val Thr Leu Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 
            20                  25                  30          


Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gly Lys Asn Asn Arg Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 
    50                  55                  60                  


Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Thr Glu 
65                  70                  75                  80  


Asp Glu Ala Ile Tyr Tyr Cys Asn Ser Leu Glu Arg Ile Gly Tyr Leu 
                85                  90                  95      


Ser Tyr Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 
            100                 105                 


<210>  289
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 G2D VH

<400>  289

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Lys Gln Ser His Val Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Phe His Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  290
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 G2D VL

<400>  290

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Val Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Glu Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Thr Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 
65                  70                  75                  80  


Glu Asp Leu Gly Ile Tyr Tyr Cys Leu Gln Tyr Ala Glu Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  291
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 K2E VH

<400>  291

Gln Val Gln Leu Gln Gln Ser Ala Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  292
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 K2E VL

<400>  292

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Phe Ser Leu Thr Ile Ser Ser Leu Glu Tyr 
65                  70                  75                  80  


Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  293
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 L4L VH

<400>  293

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Ser Val Thr Val Ser Ser 
        115                 120     


<210>  294
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 L4L VL

<400>  294

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Phe Val Gly 
1               5                   10                  15      


Glu Ile Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Ser 
65                  70                  75                  80  


Glu Asp Phe Gly Asn Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105             


<210>  295
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 H8K VH

<400>  295

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Phe Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Gln Leu Glu Trp 
        35                  40                  45              


Met Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe 
65                  70                  75                  80  


Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  296
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 H8K VL

<400>  296

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Leu 
                85                  90                  95      


Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  297
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 J4F VH

<400>  297

Gln Val Gln Leu Gln Gln Ser Gly Asp Asp Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Ser Ser Leu Ser Ser Glu Asp Ser Ala Val Tyr Phe Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  298
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 J4F VL

<400>  298

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Val Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Asp Arg Leu Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 
            100                 105         


<210>  299
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2D VH

<400>  299

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  300
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2D VL

<400>  300

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Val Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Thr Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Ala Glu Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  301
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.1D T28S VH

<400>  301

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  302
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.1D D56S VL

<400>  302

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Val Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Thr Leu Val Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Ala Glu Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  303
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.2D T28S, R66K, V67A VH

<400>  303

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  304
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.2D D56E VL

<400>  304

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Val Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Thr Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Ala Glu Phe Pro Tyr 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  305
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.3D T28S, R66K, V67A, A93T, R94S VH

<400>  305

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  306
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.4D T28S, R66K, V67A, T68S, I69L, R71V VH

<400>  306

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  307
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.5D T28S, R66K, V67A, T68S, I69L, R71V, 
       A93T, R94S VH

<400>  307

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  308
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.6D T28S, T68S, I69L, R71V VH

<400>  308

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  309
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.7D T28S, T68S, I69L, R71V, A93T, R94S VH

<400>  309

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  310
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.7D T28S, T68S, I69L, R71V, A93T, R94S VH

<400>  310

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  311
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.9D T28S, N54Q VH

<400>  311

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  312
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.10D T28S, N54Q, R66K, V67A VH

<400>  312

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  313
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.11D T28S, N54Q, R66K, V67A, A93T, R94S VH

<400>  313

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  314
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.12D T28S, N54Q, R66K, V67A, T68S, I69L, 
       R71V VH

<400>  314

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  315
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.13D T28S, N54Q, R66K, V67A, T68S, I69L, 
       R71V, A93T, R94S VH

<400>  315

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  316
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.14D T28S, N54Q, T68S, I69L, R71V VH

<400>  316

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  317
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.15D T28S, N54Q, T68S, I69L, R71V, A93T, 
       R94S VH

<400>  317

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  318
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.16D T28S, N54Q, A93T, R94S VH

<400>  318

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  319
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.17D T28S, G55A VH

<400>  319

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  320
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.18D T28S, G55A, R66K, V67A VH

<400>  320

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  321
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.19D T28S, G55A, R66K, V67A, A93T, R94S VH

<400>  321

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  322
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.20D T28S, G55A, R66K, V67A, T68S, I69L, 
       R71V VH

<400>  322

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  323
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.21D T28S, G55A, R66K, V67A, T68S, I69L, 
       R71V, A93T, R94S VH

<400>  323

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  324
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.22D T28S, G55A, T68S, I69L, R71V VH

<400>  324

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  325
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.23D T28S, G55A, T68S, I69L, R71V, A93T, 
       R94S VH

<400>  325

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  326
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.24D T28S, G55A, A93T, R94S VH

<400>  326

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  327
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.25D N54Q, R66K, V67A VH

<400>  327

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  328
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.26D N54Q, R66K, V67A, A93T, R94S VH

<400>  328

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  329
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.27D N54Q, R66K, V67A, T68S, I69L, R71V VH

<400>  329

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  330
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.28D N54Q, R66K, V67A, T68S, I69L, R71V, 
       A93T, R94S VH

<400>  330

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  331
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.29D N54Q, T68S, I69L, R71V VH

<400>  331

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  332
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.30D N54Q, T68S, I69L, R71V, A93T, R94S VH

<400>  332

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  333
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.31D N54Q, A93T, R94S VH

<400>  333

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Gln Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  334
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.32D G55A, R66K, V67A VH

<400>  334

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  335
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.33D G55A, R66K, V67A, A93T, R94S VH

<400>  335

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  336
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.34D G55A, R66K, V67A, T68S, I69L, R71V VH

<400>  336

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  337
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.35D G55A, R66K, V67A, T68S, I69L, R71V, 
       A93T, R94S VH

<400>  337

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  338
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.36D G55A, T68S, I69L, R71V VH

<400>  338

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  339
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.37D G55A, T68S, I69L, R71V, A93T, R94S VH

<400>  339

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  340
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.38D G55A, A93T, R94S VH

<400>  340

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Ala Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  341
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.39D R66K, V67A VH

<400>  341

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  342
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.40D R66K, V67A, A93T, R94S VH

<400>  342

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  343
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.41D R66K, V67A, T68S, I69L, R71V VH

<400>  343

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  344
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.42D R66K, V67A, T68S, I69L, R71V, A93T, 
       R94S VH

<400>  344

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Lys Ala Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  345
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.43D T68S, I69L, R71V VH

<400>  345

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  346
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.44D T68S, I69L, R71V, A93T, R94S VH

<400>  346

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Ser Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  347
<211>  114
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzG2.45D A93T, R94S VH

<400>  347

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Asn Pro Asn Asn Gly Ala Thr Asn Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Thr Ser Val Asn Phe Tyr Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 
            100                 105                 110         


Ser Ser 
        


<210>  348
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2E VH

<400>  348

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  349
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2E VL

<400>  349

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  350
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.1E R66K, V67T VH

<400>  350

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Thr Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  351
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.1E S46T VL

<400>  351

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  352
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.2E R66K, V67T, M69L, R71A VH

<400>  352

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Thr Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  353
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.2E D56E VL

<400>  353

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  354
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.3E R66K, V67T, M69L, R71A, T73K VH

<400>  354

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Lys Thr Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  355
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.3E S46T D56E VL

<400>  355

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Phe 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  356
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzK2.4E M69L, R71A VH

<400>  356

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Thr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Tyr Ile Ser Pro Ser Ser Gly Tyr Thr Glu Tyr Asn Gln Lys Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Leu Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 
            100                 105                 110         


Ser 
    


<210>  357
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4L VH

<400>  357

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  358
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4L VL

<400>  358

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  359
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.1L S30T, V67I, T68S, S70T, V71R VH

<400>  359

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  360
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.1L D56S VL

<400>  360

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Thr Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  361
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.2L G27Y, S30T, V67I, T68S, S70T, V71R VH

<400>  361

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  362
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.2L D56E VL

<400>  362

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Thr Asn Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  363
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.3L G27Y, S30T VH

<400>  363

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  364
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.3L G57A VL

<400>  364

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Thr Asn Leu Ala Asp Ala Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Pro 
                85                  90                  95      


Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105             


<210>  365
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.4L G27Y, V67I, T68S, S70T, V71R VH

<400>  365

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  366
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.5L G27Y, S30T, S70T, V71R VH

<400>  366

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  367
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.6L G27Y, S70T, V71R VH

<400>  367

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  368
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.7L G27Y, S30T, V67I, T68S VH

<400>  368

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  369
<211>  121
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzL4.8L G27Y, V67I, T68S VH

<400>  369

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Arg Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Tyr Arg Tyr Asp Glu Gly Tyr Gly Met Asp Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120     


<210>  370
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8K VH

<400>  370

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  371
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8K VL

<400>  371

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  372
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.1K S30T VH

<400>  372

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  373
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.2K G27F, S30T VH

<400>  373

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  374
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.3K V67I, T68S, S70T, V71R VH

<400>  374

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  375
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.4K S30T, V67I, T68S, S70T, V71R VH

<400>  375

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  376
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.5K G27F, S30T, V67I, T68S, S70T, V71R VH

<400>  376

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  377
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.6K S30T, V67I, T68S VH

<400>  377

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  378
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.7K S30T, S70T, V71R VH

<400>  378

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  379
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.8K V67I, T68S VH

<400>  379

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Ile Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  380
<211>  123
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzH8.9K S70T, V71R VH

<400>  380

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp 
            20                  25                  30          


Tyr Ala Trp Asn Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp 
        35                  40                  45              


Ile Gly Tyr Arg Ser Tyr Arg Gly Ser Thr Ser Tyr Asn Pro Ser Leu 
    50                  55                  60                  


Lys Ser Arg Val Thr Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Ser 
65                  70                  75                  80  


Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Gly Tyr Tyr Gly Ser Ser Ser His Trp Tyr Phe Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  381
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4F VH

<400>  381

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  382
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4F VL

<400>  382

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  383
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.1F V37I VH

<400>  383

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Ile Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  384
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.1F Q3V VL

<400>  384

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  385
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.2F V37I, R38K, M48I VH

<400>  385

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Ile Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  386
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.2F Q3V L46A VL

<400>  386

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  387
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.3F V37I, R66K, V67A VH

<400>  387

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Ile Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  388
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.3F L46A VL

<400>  388

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  389
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.4F V37I, R38K, M48I, R66K, V67A VH

<400>  389

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Ile Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  390
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.4F L46A, L47V VL

<400>  390

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Val Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  391
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.5F R66K, V67A VH

<400>  391

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  392
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.5F L46A, L47V, F62L VL

<400>  392

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Val Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Ser Arg Leu Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  393
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.6F R66K, V67A, V78A VH

<400>  393

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  394
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.6F L46A, L47V, S60D, F62L, S63T VL

<400>  394

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Ala Val Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Phe Ser Gly Val Pro Asp Arg Leu Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  395
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.7F R66K, V67A, V78A, M80I, E81Q VH

<400>  395

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Ile Gln Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  396
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.8F R66K, V67A, M69L, R71V VH

<400>  396

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  397
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.9F M69L, R71V VH

<400>  397

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


<210>  398
<211>  115
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Antibody to ASGR1 hzJ4.10F R71V VH

<400>  398

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Val Pro Gly Ser Gly Ser Thr Tyr Tyr Asn Glu Met Phe 
    50                  55                  60                  


Lys Asp Arg Val Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Pro Asn Phe Asp Val Trp Gly Gln Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser 
        115 


